 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"BACTRIM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: BACTRIM: adverse_reactions: ADVERSE REACTIONS The following adverse reactions associated with the use of BACTRIM or sulfamethoxazole and trimethoprim were identified in clinical trials, [0m
[31mpostmarketing or published reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or [0m
[31mestablish a causal relationship to drug exposure. The most common adverse reactions are gastrointestinal disturbances [0m[1;31m([0m[31mnausea, vomiting, anorexia[0m[1;31m)[0m[31m and allergic skin reactions [0m[1;31m([0m[31msuch as rash and [0m
[31murticaria[0m[1;31m)[0m[31m. BACTRIM: adverse_reactions: Fatalities and serious adverse reactions, including severe cutaneous adverse reactions [0m[1;31m([0m[31mSCARs[0m[1;31m)[0m[31m, including Stevens-Johnson syndrome, toxic epidermal necrolysis, [0m
[31mdrug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, acute febrile neutrophilic dermatosis [0m[1;31m([0m[31mAFND[0m[1;31m)[0m[31m, acute generalized erythematous pustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m; fulminant hepatic necrosis; [0m
[31magranulocytosis, aplastic anemia and other blood dyscrasias; acute and delayed lung injury; anaphylaxis and circulatory shock have occurred with the administration of sulfamethoxazole and trimethoprim[0m
[31mproducts, including [0m[1;31mBACTRIM[0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. BACTRIM: adverse_reactions: Hematologic: Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic [0m
[31manemia, hypoprothrombinemia, methemoglobinemia, eosinophilia, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura. BACTRIM: adverse_reactions: Allergic Reactions: Stevens-Johnson [0m
[31msyndrome, toxic epidermal necrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like [0m
[31msyndrome, generalized allergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria, rash, periarteritis nodosa, systemic lupus [0m
[31merythematosus, drug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, acute generalized erythematous pustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m, and acute febrile neutrophilic dermatosis [0m[1;31m([0m[31mAFND[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mBACTRIM: adverse_reactions: Gastrointestinal: Hepatitis [0m[1;31m([0m[31mincluding cholestatic jaundice and hepatic necrosis[0m[1;31m)[0m[31m, elevation of serum transaminase and bilirubin, pseudomembranous enterocolitis, [0m
[31mpancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia. Genitourinary: Renal failure, interstitial nephritis, BUN and serum creatinine elevation, renal insufficiency, [0m
[31moliguria and anuria, crystalluria and nephrotoxicity in association with cyclosporine. Metabolic and Nutritional: Hyperkalemia, hyponatremia [0m[1;31m([0m[31msee PRECAUTIONS: Electrolyte Abnormalities [0m[1;31m)[0m[31m, metabolic [0m
[31macidosis. Neurologic: Aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache. Psychiatric: Hallucinations, depression, apathy, nervousness. BACTRIM: [0m
[31madverse_reactions: Endocrine: The sulfonamides bear certain chemical similarities to some goitrogens, diuretics [0m[1;31m([0m[31macetazolamide and the thiazides[0m[1;31m)[0m[31m and oral hypoglycemic agents. Cross-sensitivity may [0m
[31mexist with these agents. Diuresis and hypoglycemia have occurred. Musculoskeletal: Arthralgia, myalgia, rhabdomyolysis. Respiratory: Cough, shortness of breath and pulmonary infiltrates, acute [0m
[31meosinophilic pneumonia, acute and delayed lung injury, interstitial lung disease, acute respiratory failure [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cardiovascular System: QT prolongation resulting in ventricular tachycardia[0m
[31mand torsades de pointes , circulatory shock [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . Miscellaneous: Weakness, fatigue, insomnia.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: geriatric_use: Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger [0m
[31msubjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate [0m
[31mdeficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or [0m
[31mwithout purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased [0m
[31mincidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be [0m
[31mmonitored. BACTRIM: geriatric_use: Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage [0m
[31madjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m
[31msection[0m[1;31m)[0m[31m. The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given [0m
[31mconcomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of BACTRIM [0m
[31mtreatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet.[0m
[31mBACTRIM: geriatric_use: Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher [0m
[31mand mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: teratogenic_effects: Teratogenic Effects Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic[0m
[31mstudies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, [0m
[31mcardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple [0m
[31mstatistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures [0m
[31mvaried between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim [0m
[31mexposure and specific malformations. BACTRIM: precautions: Animal Data In rats, oral doses of either [0m[1;31m533[0m[31m mg/kg sulfamethoxazole or [0m[1;31m200[0m[31m mg/kg trimethoprim produced teratologic effects manifested mainly[0m
[31mas cleft palates. These doses are approximately [0m[1;31m5[0m[31m and [0m[1;31m6[0m[31m times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when [0m[1;31m512[0m[31m mg/kg of [0m
[31msulfamethoxazole was used in combination with [0m[1;31m128[0m[31m mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss [0m[1;31m([0m[31mdead and resorbed conceptuses[0m[1;31m)[0m[31m was associated with doses of [0m
[31mtrimethoprim [0m[1;31m6[0m[31m times the human therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section. Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast [0m
[31mmilk are approximately [0m[1;31m2[0m[31m–[0m[1;31m5[0m[31m% of the recommended daily dose for infants over [0m[1;31m2[0m[31m months of age. BACTRIM: precautions: Caution should be exercised when BACTRIM is administered to a nursing woman, [0m
[31mespecially when breastfeeding jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus. Pediatric Use BACTRIM is contraindicated for [0m
[31minfants younger than [0m[1;31m2[0m[31m months of age [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS sections[0m[1;31m)[0m[31m. Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and [0m
[31mover to determine whether they respond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions [0m
[31mexist, e.g., impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. BACTRIM: precautions: Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee[0m
[31mWARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or without purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In[0m
[31mthose concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with [0m
[31mconcomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These [0m
[31meffects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize [0m
[31mrisks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION section[0m[1;31m)[0m[31m. BACTRIM: precautions: The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying [0m
[31mdisorders of potassium metabolism, with renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of [0m
[31mserum potassium is warranted in these patients. Discontinuation of BACTRIM treatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per[0m
[31mtablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: nursing_mothers: Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast milk are approximately [0m[1;31m2[0m[31m–[0m[1;31m5[0m[31m% of the recommended daily dose for infants over [0m[1;31m2[0m[31m months of age. [0m
[31mCaution should be exercised when BACTRIM is administered to a nursing woman, especially when breastfeeding jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin [0m
[31mdisplacement and kernicterus.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: warnings: WARNINGS Hypersensitivity and Other Serious or Fatal Reactions Fatalities and serious adverse reactions including severe cutaneous adverse reactions [0m[1;31m([0m[31mSCARs[0m[1;31m)[0m[31m including [0m
[31mStevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, acute febrile neutrophilic dermatosis [0m[1;31m([0m[31mAFND[0m[1;31m)[0m[31m, acute generalized erythematous [0m
[31mpustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m; fulminant hepatic necrosis; agranulocytosis, aplastic anemia and other blood dyscrasias; acute and delayed lung injury; anaphylaxis and circulatory shock have occurred with the [0m
[31madministration of sulfamethoxazole and trimethoprim products, including BACTRIM [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Cough, shortness of breath and pulmonary infiltrates potentially representing hypersensitivity[0m
[31mreactions of the respiratory tract have been reported in association with sulfamethoxazole and trimethoprim treatment. BACTRIM: warnings: Other severe pulmonary adverse reactions occurring within days[0m
[31mto week of BACTRIM initiation and resulting in prolonged respiratory failure requiring mechanical ventilation or extracorporeal membrane oxygenation [0m[1;31m([0m[31mECMO[0m[1;31m)[0m[31m, lung transplantation or death have also [0m
[31mbeen reported in patients and otherwise healthy individuals treated with sulfamethoxazole and trimethoprim products. Circulatory shock with fever, severe hypotension, and confusion requiring [0m
[31mintravenous fluid resuscitation and vasopressors has occurred within minutes to hours of re-challenge with sulfamethoxazole and trimethoprim products, including BACTRIM, in patients with history of [0m
[31mrecent [0m[1;31m([0m[31mdays to weeks[0m[1;31m)[0m[31m exposure to sulfamethoxazole and trimethoprim. BACTRIM should be discontinued at the first appearance of skin rash or any sign of a serious adverse reaction. BACTRIM: warnings: [0m
[31mA skin rash may be followed by a more severe reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, AFND, AGEP, hepatic necrosis, or serious blood disorders [0m[1;31m([0m[31msee PRECAUTIONS [0m
[31mand ADVERSE REACTIONS [0m[1;31m)[0m[31m. Clinical signs, such as rash, pharyngitis, fever, arthralgia, cough, chest pain, dyspnea, pallor, purpura or jaundice may be early indications of serious reactions. [0m
[31mThrombocytopenia BACTRIM-induced thrombocytopenia may be an immune-mediated disorder. Severe cases of thrombocytopenia that are fatal or life threatening have been reported. Thrombocytopenia usually [0m
[31mresolves within a week upon discontinuation of BACTRIM. BACTRIM: warnings: Streptococcal Infections and Rheumatic Fever The sulfonamides should not be used for treatment of group A β-hemolytic [0m
[31mstreptococcal infections. In an established infection, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as rheumatic fever. Clostridioides difficile Associated [0m
[31mDiarrhea Clostridioides difficile associated diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m has been reported with use of nearly all antibacterial agents, including BACTRIM, and may range in severity from mild diarrhea to fatal [0m
[31mcolitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of [0m
[31mCDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. BACTRIM: warnings:[0m
[31mCDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the [0m
[31madministration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte [0m
[31mmanagement, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Risk Associated with Concurrent Use of Leucovorin for [0m
[31mPneumocystis jirovecii Pneumonia Treatment failure and excess mortality were observed when BACTRIM was used concomitantly with leucovorin for the treatment of HIV positive patients with P. jirovecii [0m
[31mpneumonia in a randomized placebo-controlled trial. [0m[1;31m4[0m[31m Avoid coadministration of BACTRIM and leucovorin during treatment of P . jirovecii pneumonia.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: BACTRIM has been associated with serious adverse reactions including fulminant hepatic necrosis, which is a form of acute liver injury. However, the frequency of this adverse reaction is not [0m
[32mreliably estimated due to voluntary reporting from an uncertain population size.[0m

[32mSOURCE: BACTRIM label[0m
[32mEXTRACT_START_END: Fatalities and serious adverse reactions, including severe cutaneous adverse reactions[0m[32m...[0m[32mfulminant hepatic necrosis; agranulocytosis[0m[32m...[0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: BACTRIM has been associated with serious adverse reactions [0m
[34mincluding fulminant hepatic necrosis, which is a form of acute liver injury. However, the frequency of this adverse reaction is not reliably estimated due to voluntary reporting from an uncertain [0m
[34mpopulation size.[0m

[34mSOURCE: BACTRIM label[0m
[34mEXTRACT_START_END: Fatalities and serious adverse reactions, including severe cutaneous adverse reactions[0m[34m...[0m[34mfulminant hepatic necrosis; agranulocytosis[0m[34m...[0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if BACTRIM increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that BACTRIM has been associated with serious adverse reactions including fulminant hepatic necrosis, which is a form of acute liver injury. However, the frequency of this [0m
[32madverse reaction is not reliably estimated due to voluntary reporting from an uncertain population size."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"BACTRIM has been associated with an increased risk of acute liver injury, including fulminant hepatic necrosis. However, the frequency of this adverse reaction is not reliably [0m
[32mestimated, indicating that while there is a risk, the exact prevalence is unknown."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does BACTRIM increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if BACTRIM increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that BACTRIM has been associated with serious adverse reactions including fulminant hepatic necrosis, which is a form of acute liver injury. However, the frequency of this [0m
[34madverse reaction is not reliably estimated due to voluntary reporting from an uncertain population size."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"BACTRIM has been associated with an increased risk of acute liver injury, including fulminant hepatic necrosis. However, the frequency of this adverse reaction is not reliably [0m
[34mestimated, indicating that while there is a risk, the exact prevalence is unknown."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does BACTRIM increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if BACTRIM increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that BACTRIM has been associated with serious adverse reactions including fulminant hepatic necrosis, which is a form of acute liver injury. However, the frequency of this [0m
[31madverse reaction is not reliably estimated due to voluntary reporting from an uncertain population size.[0m
[31m        -----[0m
[31m        Final answer: BACTRIM has been associated with an increased risk of acute liver injury, including fulminant hepatic necrosis. However, the frequency of this adverse reaction is not reliably [0m
[31mestimated, indicating that while there is a risk, the exact prevalence is unknown.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mBACTRIM has been associated with an increased risk of acute liver injury, including fulminant hepatic necrosis. However, the frequency of this adverse reaction is not reliably estimated, indicating [0m
[32mthat while there is a risk, the exact prevalence is unknown.[0m
